CN111741760A - 用于神经疾病的组合物和方法 - Google Patents

用于神经疾病的组合物和方法 Download PDF

Info

Publication number
CN111741760A
CN111741760A CN201880085562.7A CN201880085562A CN111741760A CN 111741760 A CN111741760 A CN 111741760A CN 201880085562 A CN201880085562 A CN 201880085562A CN 111741760 A CN111741760 A CN 111741760A
Authority
CN
China
Prior art keywords
receptor
engineered
ligand
pain
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880085562.7A
Other languages
English (en)
Chinese (zh)
Inventor
K.P.格林伯格
O.小凯弗
S.梅金森
A.劳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keda Transferred For Benefit Of Creditors LLC
Trames Bio Inc
Original Assignee
Keda Biotherapy Medicine Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keda Biotherapy Medicine Co ltd filed Critical Keda Biotherapy Medicine Co ltd
Publication of CN111741760A publication Critical patent/CN111741760A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201880085562.7A 2017-11-27 2018-11-27 用于神经疾病的组合物和方法 Pending CN111741760A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762590911P 2017-11-27 2017-11-27
US62/590,911 2017-11-27
US201862659911P 2018-04-19 2018-04-19
US62/659,911 2018-04-19
PCT/US2018/062575 WO2019104307A1 (en) 2017-11-27 2018-11-27 Compositions and methods for neurological diseases

Publications (1)

Publication Number Publication Date
CN111741760A true CN111741760A (zh) 2020-10-02

Family

ID=66632192

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880085562.7A Pending CN111741760A (zh) 2017-11-27 2018-11-27 用于神经疾病的组合物和方法

Country Status (12)

Country Link
US (2) US10538571B2 (cg-RX-API-DMAC7.html)
EP (1) EP3716990A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021503960A (cg-RX-API-DMAC7.html)
KR (2) KR20200112811A (cg-RX-API-DMAC7.html)
CN (1) CN111741760A (cg-RX-API-DMAC7.html)
AU (2) AU2018373279B2 (cg-RX-API-DMAC7.html)
CA (1) CA3082907A1 (cg-RX-API-DMAC7.html)
IL (2) IL274702B2 (cg-RX-API-DMAC7.html)
MX (2) MX2020005470A (cg-RX-API-DMAC7.html)
SG (1) SG11202004488TA (cg-RX-API-DMAC7.html)
WO (1) WO2019104307A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202408862B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113730809A (zh) * 2021-10-09 2021-12-03 西安科悦医疗股份有限公司 一种非侵入式迷走神经联合骶神经刺激装置

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020222881C1 (en) 2019-02-13 2026-01-22 Ptc Therapeutics, Inc. Thioeno(3,2-b) pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
JP7781052B2 (ja) * 2019-08-21 2025-12-05 トレイムス バイオ, インコーポレイテッド 神経学的疾患のための組成物および方法
US20230102192A1 (en) * 2020-02-20 2023-03-30 The Regents Of The University Of California Therapies for the treatment of diseases and disorders associated with abnormal expression of a neural-associated gene
AU2021329529A1 (en) * 2020-08-21 2023-04-27 Trames Bio, Inc. Compositions and methods for neurological diseases
WO2022067044A1 (en) * 2020-09-25 2022-03-31 The Regents Of The University Of California Compositions and methods for ameliorating medical conditions
JP2024505197A (ja) * 2021-01-25 2024-02-05 トレイムス バイオ, インコーポレイテッド 焦点てんかんおよび神経因性疼痛を処置するためのアデノ随伴ウイルスカプシドおよび操作されたリガンド依存性イオンチャネル
US11969400B2 (en) * 2021-03-23 2024-04-30 Kumara V. Nibhanipudi Ibuprofen for symptomatic treatment of diarrheas in HIV patients
WO2023278295A1 (en) 2021-06-29 2023-01-05 The Broad Institute, Inc. Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability
US20250145687A1 (en) * 2022-01-31 2025-05-08 Howard Hughes Medical Institute Modified ligand-gated ion channels and methods of use
CN119343455A (zh) * 2022-01-31 2025-01-21 特拉梅斯生物股份有限公司 用于治疗癫痫和神经性疼痛的表达盒
IL315059A (en) * 2022-02-18 2024-10-01 Trames Bio Inc Ion channels that open using ligands and methods of using them
AU2023222147A1 (en) * 2022-02-18 2024-09-12 Trames Bio, Inc. Compositions and methods for neurological diseases
WO2025015092A1 (en) * 2023-07-10 2025-01-16 Kriya Therapeutics, Inc. Novel cam-kinase promoter and uses thereof for treating nervous system disorders
CN121866054A (zh) * 2023-08-16 2026-04-14 拜尔吉生物股份有限公司 用于治疗癫痫发作的方法
GB202401492D0 (en) 2024-02-05 2024-03-20 Ucl Business Ltd Chloride channels and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837489A (en) * 1993-03-08 1998-11-17 Sibia Neurosciences, Inc. Human neuronal nicotinic acetylcholine receptor and cells transformed with same DNA and mRNA encoding an--subunit of
US20100130420A1 (en) * 2008-10-09 2010-05-27 Howard Hughes Medical Institute Novel chimeric ligand-gated ion channels and methods of use thereof
US20170190758A1 (en) * 2012-12-10 2017-07-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Engineered receptors and their use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0733103B1 (en) 1993-11-09 2004-03-03 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
WO1997035478A1 (en) 1996-03-26 1997-10-02 The Regents Of The University Of California Selective target cell activation by expression of a g protein-coupled receptor activated superiorly by synthetic ligand
FR2756297B1 (fr) 1996-11-22 1999-01-08 Centre Nat Rech Scient Procede de production de virus recombinants
WO1999006562A1 (en) 1997-07-31 1999-02-11 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
CA2995542A1 (en) 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
WO2000073431A2 (en) 1999-05-27 2000-12-07 Pharmacia & Upjohn Company Methods and compositions for measuring ion channel conductance
US6498244B1 (en) 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
WO2001023001A2 (en) 1999-09-29 2001-04-05 The Trustees Of The University Of Pennsylvania Rapid peg-modification
AU2001257378A1 (en) 2000-04-29 2001-11-12 Millennium Pharmaceuticals, Inc. 23949 and 32391, human ion channels and uses thereof
US7883846B2 (en) 2002-05-31 2011-02-08 Sloan-Kettering Institute For Cancer Research Heterologous stimulus-gated ion channels and methods of using same
PL2657248T3 (pl) 2003-06-19 2017-09-29 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
WO2008143875A1 (en) 2007-05-14 2008-11-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
GB201404470D0 (en) 2014-03-13 2014-04-30 Ucl Business Plc Therapeutic methods and materials
US10682424B2 (en) 2015-03-31 2020-06-16 New York University Compositions and method for reducing seizures
AU2016324317A1 (en) 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders
IL311984A (en) 2016-07-07 2024-06-01 Hughes Howard Med Inst Modified ligand-gated ion channels and methods of use
US11713470B2 (en) 2017-03-20 2023-08-01 University of Pittsburgh—of the Commonwealth System of Higher Education Targeted gene therapies for pain and other neuro-related disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837489A (en) * 1993-03-08 1998-11-17 Sibia Neurosciences, Inc. Human neuronal nicotinic acetylcholine receptor and cells transformed with same DNA and mRNA encoding an--subunit of
US20100130420A1 (en) * 2008-10-09 2010-05-27 Howard Hughes Medical Institute Novel chimeric ligand-gated ion channels and methods of use thereof
US20170190758A1 (en) * 2012-12-10 2017-07-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Engineered receptors and their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DINA MANETTI ET AL.: "New quinoline derivatives as nicotinic receptor modulators", EUR J MED CHEM, vol. 110, pages 246 - 258, XP029415630, DOI: 10.1016/j.ejmech.2016.01.025 *
K BREJC ET AL.: "Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors", NATURE, vol. 411, no. 6835, pages 270 - 273 *
TAOYI YANG ET AL: "The current agonists and positive allosteric modulators of α 7 nAChR for CNS indications in clinical trials", ACTA PHARM SIN B, vol. 7, no. 6, pages 611 - 622, XP055627182, DOI: 10.1016/j.apsb.2017.09.001 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113730809A (zh) * 2021-10-09 2021-12-03 西安科悦医疗股份有限公司 一种非侵入式迷走神经联合骶神经刺激装置

Also Published As

Publication number Publication date
US20190161529A1 (en) 2019-05-30
IL274702B2 (en) 2026-04-01
WO2019104307A1 (en) 2019-05-31
AU2018373279A1 (en) 2020-06-04
SG11202004488TA (en) 2020-06-29
EP3716990A1 (en) 2020-10-07
KR20200112811A (ko) 2020-10-05
JP2024160218A (ja) 2024-11-13
ZA202408862B (en) 2026-01-28
IL274702B1 (en) 2025-12-01
AU2018373279B2 (en) 2024-07-25
JP2021503960A (ja) 2021-02-15
EP3716990A4 (en) 2021-12-08
CA3082907A1 (en) 2019-05-31
IL324810A (en) 2026-01-01
IL274702A (en) 2020-06-30
AU2024227560A1 (en) 2024-11-14
US20210061873A1 (en) 2021-03-04
MX2024014448A (es) 2024-12-06
KR20260030128A (ko) 2026-03-05
MX2020005470A (es) 2020-11-09
US10538571B2 (en) 2020-01-21
AU2024227560B2 (en) 2026-06-04

Similar Documents

Publication Publication Date Title
JP2024160218A (ja) 神経疾患のための組成物および方法
JP7781052B2 (ja) 神経学的疾患のための組成物および方法
JP2026082870A (ja) 神経疾患のための組成物および方法
JP2025508429A (ja) 神経学的疾患のための組成物および方法
JP2025508427A (ja) リガンド依存性イオンチャネルおよび使用の方法
CN119343455A (zh) 用于治疗癫痫和神经性疼痛的表达盒
BR122025015501A2 (pt) Receptor modificado, polinucleotídeo, vetor, uso dos mesmos, bem como método para expressão de um receptor modificado em um neurônio

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20251203

Address after: California, USA

Applicant after: Keda (transferred for the benefit of creditors) LLC

Country or region after: U.S.A.

Address before: California, USA

Applicant before: Keda biotherapy Medicine Co.,Ltd.

Country or region before: U.S.A.

Effective date of registration: 20251204

Address after: California, USA

Applicant after: Trames Bio

Country or region after: U.S.A.

Address before: California, USA

Applicant before: Keda (transferred for the benefit of creditors) LLC

Country or region before: U.S.A.